Home › Compare › RSPI vs HDV

RSPI vs HDV: Dividend Comparison 2026

RSPI yields 111111.11% · HDV yields 2.92%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 RSPI wins by $1.3838190899465547e+27M in total portfolio value
10 years
RSPI
RSPI
● Live price
111111.11%
Share price
$0.00
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$1.3838190899465547e+27M
Annual income
$1,381,373,456,343,941,000,000,000,000,000,000.00
Full RSPI calculator →
HDV
iShares Core High Dividend ETF
● Live price
2.92%
Share price
$135.72
Annual div
$3.96
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$24.3K
Annual income
$351.71
Full HDV calculator →

Portfolio growth — RSPI vs HDV

📍 RSPI pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodRSPIHDV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, RSPI + HDV cover 0 of 12 months — good coverage

Jan
—
Feb
—
Mar
—
Apr
—
May
—
Jun
—
Jul
—
Aug
—
Sep
—
Oct
—
Nov
—
Dec
—
RSPI pays
HDV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

RSPI
Annual income on $10K today (after 15% tax)
$9,444,444.44/yr
After 10yr DRIP, annual income (after tax)
$1,174,167,437,892,349,800,000,000,000,000,000.00/yr
HDV
Annual income on $10K today (after 15% tax)
$247.92/yr
After 10yr DRIP, annual income (after tax)
$298.95/yr
At 15% tax rate, RSPI beats the other by $1,174,167,437,892,349,800,000,000,000,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of RSPI + HDV for your $10,000?

RSPI: 50%HDV: 50%
100% HDV50/50100% RSPI
Portfolio after 10yr
$6.919095449732774e+26M
Annual income
$690,686,728,171,970,500,000,000,000,000,000.00/yr
Blended yield
99.82%
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

RSPI buys
0
HDV buys
0
No recent congressional trades found for RSPI or HDV in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricRSPIHDV
Forward yield111111.11% ✓2.92%
Annual dividend / share$2.00$3.96 ✓
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%0%
Portfolio after 10y$1.3838190899465547e+27M$24.3K ✓
Annual income after 10y$1,381,373,456,343,941,000,000,000,000,000,000.00 ✓$351.71
Total dividends collected$1.383658847866035e+27M$3.2K ✓
Payment frequencyquarterlyquarterly
SectorStockETF

Year-by-year: RSPI vs HDV ($10,000, DRIP)

YearRSPI PortfolioRSPI Income/yrHDV PortfolioHDV Income/yrGap
1← crossover$11,121,811$11,111,111.11$11,002$291.67+$11.11M → RSPI
2$11,561,029,218$11,549,128,879.66$12,082$299.61+$11561.02M → RSPI
3$11,232,204,364,934$11,219,834,063,671.13$13,247$307.23+$11232204.35M → RSPI
4$10,199,601,320,781,262$10,187,582,862,110,782.00$14,503$314.52+$10199601320.77M → RSPI
5$8,656,721,364,988,387,000$8,645,807,791,575,153,000.00$15,854$321.50+$8656721364988.37M → RSPI
6$6,867,176,795,058,000,000,000$6,857,914,103,197,462,000,000.00$17,308$328.15+$6867176795058000.00M → RSPI
7$5,091,669,942,459,710,000,000,000$5,084,322,063,288,997,000,000,000.00$18,871$334.49+$5091669942459709440.00M → RSPI
8$3,528,599,356,203,225,300,000,000,000$3,523,151,269,364,793,600,000,000,000.00$20,551$340.53+$3.5285993562032256e+21M → RSPI
9$2,285,638,880,947,370,600,000,000,000,000$2,281,863,279,636,233,000,000,000,000,000.00$22,357$346.27+$2.2856388809473705e+24M → RSPI
10$1,383,819,089,946,554,900,000,000,000,000,000$1,381,373,456,343,941,000,000,000,000,000,000.00$24,296$351.71+$1.3838190899465547e+27M → RSPI

RSPI vs HDV: Complete Analysis 2026

RSPI — Stock

RespireRx Pharmaceuticals Inc. engages in the discovery, development, and commercialization of pharmaceuticals for the treatment of neurological and psychiatric disorders. It has two drug platforms comprising ResolutionRx, a pharmaceutical cannabinoids platform, which includes dronabinol that acts upon the CB1 and CB2 endocannabinoid receptors for use in chemotherapy-induced nausea and vomiting, as well as for anorexia in patients with AIDS and obstructive sleep apnea; and EndeavourRx, a neuromodulators platform that comprises AMPAkines program, including proprietary compounds that are positive allosteric modulators (PAMs) of alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA)-type glutamate receptors to promote neuronal function, and GABAkines program, including proprietary compounds that are PAMs of GABAA receptors. The company's lead ampakine, CX1739, which has completed Phase II clinical studies for opioid-induced respiratory depression, as well as for central sleep apnea. It is also developing CX717, CX1739, and CX1942 that have clinical application in the treatment of CNS-driven neurobehavioral and cognitive disorders, spinal cord injury, neurological diseases, and various orphan indications. The company was formerly known as Cortex Pharmaceuticals, Inc. and changed its name to RespireRx Pharmaceuticals Inc. in December 2015. RespireRx Pharmaceuticals Inc. was incorporated in 1987 and is headquartered in Glen Rock, New Jersey.

Full RSPI Calculator →

HDV — ETF

The iShares Core High Dividend ETF seeks to track the investment results of an index composed of relatively high dividend paying U.S. equities.

Full HDV Calculator →
📬

Get this RSPI vs HDV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

RSPI vs SCHDRSPI vs JEPIRSPI vs ORSPI vs KORSPI vs MAINRSPI vs VYMRSPI vs DVYRSPI vs SPHD

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.